MetLife Investment Management’s Nurix Therapeutics NRIX Stock Holding History

MetLife Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$867K	Buy	55,948 +603	+1%	+$10K	﹤0.01%	1469
2025 Q4	$1.05M	Buy	55,345 +10,127	+22%	+$145K	0.01%	1399
2025 Q3	$418K	Hold	45,218	–	–	﹤0.01%	1891
2025 Q2	$515K	Buy	45,218 +3,113	+7%	+$33.6K	﹤0.01%	1665
2025 Q1	$500K	Sell	42,105 -434	-1%	-$7.26K	﹤0.01%	1730
2024 Q4	$801K	Buy	42,539 +7,300	+21%	+$167K	﹤0.01%	1534
2024 Q3	$792K	Buy	35,239 +168	+0.5%	+$3.81K	﹤0.01%	1527
2024 Q2	$732K	Buy	35,071 +11,783	+51%	+$183K	﹤0.01%	1516
2024 Q1	$342K	Hold	23,288	–	–	﹤0.01%	1896
2023 Q4	$240K	Hold	23,288	–	–	﹤0.01%	2133
2023 Q3	$183K	Hold	23,288	–	–	﹤0.01%	2270
2023 Q2	$233K	Hold	23,288	–	–	﹤0.01%	2182
2023 Q1	$207K	Hold	23,288	–	–	﹤0.01%	2201
2022 Q4	$256K	Hold	23,288	–	–	﹤0.01%	2097
2022 Q3	$303K	Hold	23,288	–	–	﹤0.01%	2013
2022 Q2	$295K	Buy	23,288 +4,618	+25%	+$52.3K	﹤0.01%	2036
2022 Q1	$262K	Buy	18,670 +6,891	+59%	+$122K	﹤0.01%	2186
2021 Q4	$341K	Hold	11,779	–	–	﹤0.01%	1725
2021 Q3	$353K	Hold	11,779	–	–	﹤0.01%	1733
2021 Q2	$312K	Buy	11,779 +2,269	+24%	+$66.6K	﹤0.01%	1861
2021 Q1	$296K	Buy	9,510 +4,421	+87%	+$167K	﹤0.01%	1820
2020 Q4	$167K	Hold	5,089	–	–	﹤0.01%	2077
2020 Q3	$178K	Buy	+5,089	New	+$128K	﹤0.01%	1929

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

MetLife Investment Management's NRIX Position: Q1 2026 in Review

MetLife Investment Management increased its Nurix Therapeutics (NRIX) stake by 1.1% in Q1 2026, buying an estimated $10K and bringing the position to 55,948 shares worth $867K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

MetLife Investment Management first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.05M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

MetLife Investment Management held 55,948 shares of Nurix Therapeutics worth $867K as of Q1 2026.
MetLife Investment Management bought 603 Nurix Therapeutics shares in Q1 2026, an estimated $10K.
Nurix Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1469 holding.
MetLife Investment Management first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
MetLife Investment Management's Nurix Therapeutics position peaked at $1.05M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.